Results 231 to 240 of about 8,093,285 (389)

MS4 THE IMPACT OF HEALTH CARE ATTITUDES ON PATIENT REPORTED OUTCOMES (PRO'S)

, 2003
SC Bolge, K. Annunziata, JA Donohue
openalex   +1 more source

Two-Year Clinical Outcomes After Enhanced External Counterpulsation (EECP) Therapy in Patients With Refractory Angina Pectoris and Left Ventricular Dysfunction (Report from the International EECP Patient Registry) [PDF]

, 2005
Özlem Soran, Elizabeth D. Kennard, Abdallah G. Kfoury, Sheryl F. Kelsey   +3 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Sex Differences in Patient-Reported Outcomes Among People Living With HIV Switching to an Oral Dual Therapy: Results From the PROBI Study

AIDS Research and Treatment
Tristan Alain, Fabienne Marcellin, Pascal Bessonneau, Laurent Hocqueloux, Holger Muehlan, Clotilde Allavena, David Zucman, Ester Villalonga-Olives, Olivier Chassany, Martin Duracinsky   +9 more
doaj   +1 more source

PHP37 USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING

, 2003
Mary Edmondson, Diana D. McDonnell
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Nurses' perspectives on the implementation of patient-reported outcomes: a descriptive qualitative study. [PDF]

BMC Nurs
Zhang YM, Wang YY, Liu Y, Zhong CC, Zhou M, Chen L, Guo SL.   +6 more
europepmc   +1 more source

PCN29: DEVELOPING A MEASUREMENT STRATEGY FOR PATIENT-REPORTED OUTCOMES: FINDINGS FROM THE NCI'S CANCER OUTCOMES MEASUREMENT WORKING GROUP

, 2003
C. Snyder, Justina Lipscomb, CC Gotay
openalex   +1 more source

Metaanalysis of the correlation between radiographic tumor response and patient‐reported outcomes [PDF]

, 2005
David Victorson, M. Soni, David Cella
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source